-
Mashup Score: 0
This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Dupilumab self-injection has been available to patients in Japan since May 2019.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
Patients with #AtopicDermatitis who were treated using subcutaneous self-injection of #dupilumab experienced an increased in their overall satisfaction and self-confidence. Self-injection has been available for patients in Japan since May 2019. https://t.co/uPfhGaajrS
-
-
Mashup Score: 1
Findings indicate no rebound effect when participants discontinue dupilumab.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
Patients treated with #dupilumab had a 34% reduction in new or worsened allergies and a 37% reduction in new allergies, a positive step in slowing the #atopic march. https://t.co/XG4hYWEpmD
-
-
Mashup Score: 1Dupilumab decreases exacerbation rate, improves lung function in COPD type 2 inflammation - 2 year(s) ago
WASHINGTON — At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab had a lower exacerbation rate and better lung function, according to an American Thoracic Society International Conference presentation.“Dupilumab reduced the annualized rate of exacerbations, moderate and severe, by 30%, compared to placebo, and also was associated with a
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Presented at #ATS2023: At 52 weeks, adults with moderate/severe #COPD and type 2 inflammation receiving #dupilumab had a lower #exacerbation rate and better #lung function. https://t.co/sOJngjiAgt
-
-
Mashup Score: 3
Over 24 weeks, dupilumab demonstrated efficacy in patients with chronic spontaneous urticaria.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
#Dupilumab demonstrated statistically significant improvements to quality of life and urticaria activity in patients with chronic spontaneous #urticaria over a 24-week study period. #DermPAsummer https://t.co/cdwU1dTbm6
-
-
Mashup Score: 1Dupilumab Demonstrates Sustained Improvements in Patients With Eosinophilic Esophagitis - 2 year(s) ago
Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Regardless of a prior history of swallowed topical corticosteroids, #dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis. https://t.co/9LMPp9njcH #DDW2023
-
-
Mashup Score: 2Late-Breaking Data: Dupilumab Significantly Improves Signs, Symptoms, and QoL in Patients With Hand & Foot Dermatitis - 2 year(s) ago
Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
A recent study determined “#dupilumab rapidly and significantly improved signs, symptoms, and quality of life in patients with atopic hand and foot #dermatitis." #RAD2023 https://t.co/7IfO2DFHJn
-
-
Mashup Score: 0Dupilumab Sustains Atopic Dermatitis Efficacy at 5 Years - 2 year(s) ago
An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
“The improvement is in both the signs and the symptoms. There were no adverse events that appeared to emerge.” Open-label extension data shows #dupilumab sustains atopic dermatitis efficacy through 5 years (!) New data from #RAD2023: https://t.co/niwMYQFVDO
-
-
Mashup Score: 0
Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Individuals with severe #type2asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment #dupilumab, study finds. Read more! https://t.co/RsKo1dDwiq https://t.co/QGNksYo8D1
-
-
Mashup Score: 2Dupilumab Shifts Skin Microbiome Toward Control Levels - 2 year(s) ago
Researchers said the drug is capable of restoring a healthy skin biome.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
#Dupilumab is efficacious in restoring a healthy #skin microbiome in patients with moderate-to-severe #AtopicDermatitis. https://t.co/IrtWLdp82Z
-
New research shows that #dupilumab treatment improves clinical symptoms in patients with bullous pemphigoid. View the full story here: https://t.co/YKW0mnyuo3